Granules India Submits FY26 Annual Report & Announces 35th AGM on Aug 6
Granules India submitted its FY26 Integrated Annual Report and announced its 35th AGM for August 6, 2026. The report highlights revenue of ₹53,656 million (up 20%) and EBITDA of ₹11,851 million (up 25%). The company also detailed progress in complex generics, peptide CDMO through Senn Chemicals acquisition, and sustainability efforts.
The submission of the annual report and the AGM notice are important corporate events that provide shareholders with comprehensive company information and a platform for discussion. The detailed report itself contains significant financial and strategic updates that are material to investors.
The announcement is primarily a routine submission of the annual report and notice of AGM. While the report details positive financial performance and strategic progress, the core announcement is informational rather than a significant new development.
Granules India Limited has submitted its Integrated Annual Report for the financial year 2025-26, along with the Notice of its 35th Annual General Meeting (AGM). The AGM is scheduled to be held on Thursday, August 06, 2026, at 11:30 a.m. IST, through Video Conferencing (VC).
The company has made these documents available on its website and is sending them to all registered members. Additionally, a letter providing the web-link for the Integrated Annual Report is being sent to members whose email addresses are not registered.
The Integrated Annual Report details the company's performance, strategy, and sustainability initiatives for FY 2025-26. It highlights Granules India's transformation into a science-led, globally competitive pharmaceutical company, focusing on complex generics, regulatory excellence, peptide therapeutics, manufacturing capabilities, and embedding sustainability across operations. The report also outlines the company's financial performance, including revenue of ₹53,656 million (up 20% YoY) and EBITDA of ₹11,851 million (up 25% YoY). The acquisition of Senn Chemicals AG in Switzerland, which marked an entry into the peptide CDMO space, is also a key highlight, with the business turning EBITDA-positive in Q4FY26.
The company emphasizes its commitment to quality, compliance, and responsible growth, with sustainability being a key determinant of long-term competitiveness. Granules India has set ambitious targets, including achieving net zero emissions by 2050 and has received recognition such as an EcoVadis Gold rating and a CDP Climate Change score of ‘A’.
What to do with a filing like this
Granules India Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Granules India Limited. Read the original for the full detail.